Expeditious synthetic route to B-ring functionalised 2-oxa-steroids: Synthesis of 17-ethylenedioxy-6a-hydroxy-2-oxa-4-androsten-3-one as key synthon by Nangia, Ashwini & Anthony, A
IndianJournalof Chemistry
Vol.36B,December1997,pp.ll13 - 1118
Expeditious synthetic route to B-ring functionalised 2-oxa-steroids: SYnthesis
of 17-ethylenedioxy-6a-hydroxy-2-oxa-4-androsten-3-one as key synthon
AshwiniNangia*& A Anthony
Schoolof Chemistry,Universityof Hyderabad,PO CentralUniversity,
Hyderabad500046,India.
Received18November1996;accepted7 February1997
The easily prepared 17-ethylenedioxy-4-androsten-3,6-dione 8 is transformed to 17-ethylenedioxy-
6a-hydroxy-2-oxa-4-androsten-3-one 15 in a few steps with complete stereo- and regio-control. The
hydroxylactone 15 provides an easy entry to B-ring functionalised 2-oxa-androgens for evaluation as
potential aromatase inhibitors and anabolic agents.
Aromatase is a cytochrome P450 dependent
enzyme that catalyses the aromatisation of
androgens to estrogens, and hence plays a key role
in endocrine physiology and estrogen-dependent
diseases', Since estrogens playa significant role in
the growth and maintenance of mammary tumours,
the inhibition of estrogen levels in the body by
aromatase inhibitors is one of the major
approaches in the treatment of breast cancer. The
synthesis and biochemical evaluation of androst-4-
en-3-one 1 derivatives as aromatase inhibitors has
provided new leads for breast cancer agents'. The
substitution of an oxygen atom for the methylene
group at C2 will produce steroid hormones in
which the A-ring is an a,r>-unsaturated 8-lactone
such that the position of C3-carbonyl and ~4_
alkene are unaltered. The synthesis and biological
assays of 2-oxasteroid 2 and its derivatives
(Figure 1) has yielded active candidates in the
category of steroid hormones and drugs 3. It is
well known that the presence of C3-ketone is
essential for binding to the receptor site in the
parent steroids as well as their lactone analogs.
The immense therapeutic application of steroids in
the treatment of cancers and turn ours as well as
their beneficial role in hormone regulation and as
anabolic agents is curtailed by the fact that their
administration is usually accompanied with
adverse and unwanted side effects. For example,
use of anabolic male hormone testosterone or its
derivatives for muscle development in female












Figure I-Structures of steroids1-5
sex characteristics as a serious side effect. The
research from Searle almost 30 years ago
demonstrated that separation of activity in these
hormones is indeed possible. The introduction of
steroids Nilevar ® ( 17a-ethyl-19-nortestosterone
®3)4 and Anavar (17/3-hydroxy-17 -methyl-z-oxa-
5a-androstan-3-one 4 )5 in 1960s provided
valuable anabolic agents with negligible
androgenic side effects. Subsequently, a large
number of research groups focussed on ways to
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synthesise the pharmaceutically important 2-
oxasteroids from their natural precursors, the most
recent contribution being the photosensitised
oxidation approach of Frimer and coworkers",
The synthesis of B-ring functionalised 2-
oxasteroids proceeds from 3-keto-l,4,6-triene
steroids 5 wherein the L\ I-alkene is oxidatively
cleaved and the L\6-alkene is utili sed for
derivatisation." This general protocol, which has
been widely used, suffers from the following
drawbacks: (i) The requisite triene 5 (R=H, Cl or
Me) has to be prepared in few steps from the 5-en-
3-01 steroid. ( ii ) Regioselective chemical
manipulation of the triene is somewhat difficult
and at times mixtures of products are obtained'.
(iii) The large number of steps and mandatory
purifications severely limit the overall efficiency
of the protocol. We reasoned that a convenient
and flexible method for the synthesis of 2-
oxasteroid B-ring derivatives will greatly facilitate
the testing of these compounds for further
improvement in biological activity. In this
background, we report the synthesis of C6 and C7-
functionalised 2-ox~-4-androsten-3-one molecules
as potential aromatase inhibitors and anabolic
agents.
Resuts and Discussion
Dehydroisoandrosterone 6 was protected as its
C 17 dioxolane 7 in a quantitative yield under
standard ketalisation conditions. Oxidation of the
homoallylic alcohol 7 with PCC afforded the
unexpected L\4-3,6-dione 8 in which the acid
sensitive C17-ketal group was still intact. The
generality of this novel transformation of steroidal
L\5-3-01s5 to the biologically active L\4-3,6-diones
8 under the aegies of mild and versatile PCC
oxidant was explored with a few representative
substrates." The direct formation of enedione 8
instead of the expected L\4-enone 9 is rationalised
in Scheme I. Thus, the enol form 11 of 215-enone
IP reacts at C6 vinylogously with Cr=O of PCC
reagent to provide the chromate ester 12. Further
oxidation of C6 hydroxy group smoothly provides
the L\4-3,6-dione 8.
Adaptation of Frimer's conditions for the
photosensitised oxidation of enedione 8 (t-BuOK,
02) led to a mixture of products because of
competing enolisation at C2 and C7.
Dehydrogenation of 17-ethylenedioxy-4-
androsten-3,6-dione 8 with DDQ8.10 proceeded
smoothly and afforded a single regioisomeric
product 13 in which the C 1-C2 alkene was
exclusively formed; no C7 -C8 olefin isomer was
detected. This was concluded from the IH
NMR spectrum of the crude residue which
displayed three coupled olefinic resonances arising
from C2, C4 and C1 vinyl protons at 8 6.28, 6.34
and 7.08 (13a) and at 8 6.30, 6.40 and 7.08 (13b).
Formation of L\7 -olefin would show a singlet in the
vinyl proton region which was clearly absent. The
regioselectivity in L\ 1.4-3,6-dione 13 formation is a
consequence of the facile enolisation at C2 and its
less crowded steric environment compared to C7.
Because of the long reaction period (72 hr) and
high temperature (100° C) the product contained
C 17 ketal 13a (45%) and the deprotected ketone
13b (45%), which were easily separated by column
chromatography. The concomitant hydrolysis of
C 17-dioxolane to triketone 13b was a setback but
on the positive side opens the possibility of
utilising the 2-oxa congeners as aromatase
inhibitors where C 17-protection may not be
mandatory.
Further elaboration of A-ring dienone to the 2-
oxa skeleton was achieved by the selective
ozonolysis of the more reactive C 1-C2 alkene over
C4-C5. When a stream of 03 was bubbled through
a 0.03 M solution of dienone 13a in 1:1 pyridine-
CH2Cl2 for 15-20 min. at _78° C, the only isolable
product after work-up was the desired lactol 14,
produced essentially as a single stereoisomer based
on the acetal CI-H singlet at 8 5.60 and its l3C
NMR spectrum which displayed signals for 20
carbons'". Routine NaBH4 reduction of the keto
lactol 14 afforded the hydroxy lactone 15 (Scheme
II) in 80% yield after purification. Reduction of
C6 ketone takes place entirely from the exposed 13-
face to produce the equatorial alcohol
exclusively. II In lactone 15 the AB CH20 pattern
is centred at 8 4.10 (J=12 Hz) and the axial C6-H
appears as a multiplet at 8 4.30. The weak
coupling" of C613-Hto vinylic C4-H at 8 6.12 (J=2
Hz) confirms the equatorial orientation of the
secondary alcoholic group in 15. Thus, 17-
ethylenedioxy-2-oxa-6a-hydroxy-4-andro-sten-3-
one 15 is produced with complete regio- and
stereo-control from the easily prepared L\1.4_3,6-


































Scheme II - (i) DDQ, dioxane, reflux, 72 hr, 45%; .(ii) OJ' -780 C, 1:1 pyridinelCH2Cl2, 15 min., 77%; (iii) NaBH•. 5:1
CHCllHP, 82%
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dione 13a. The hydroxy lactone 15 lends itself as
a key synthon for the synthesis of B-ring
functionalised heterosteroids, and this was
explored next.
Exposure of secondary alcohol 15 to PCC in
CH2Cl2 produced 2-oxa-4-androsten-3,6-dione 16
uneventfully. Conversion of 15 to its mesylate 17
(MsCl) and elimination (DBU) to C6-C7 olefin
was sluggish because of the equatorial orientation
of the hydroxy group. Displacement of the
mesylate group with LiBr and in situ
dehydrobromination proceeded smoothly with
Li2C03 in hot DMF to produce the conjugate
lactone 18 (Scheme III). Attempts to isolate the
intermediate axial bromide were unsuccessful
since it underwent spontaneous anti elimination.
Efforts at inverting the mesylate 17 to obtain the
epimeric 6~alcohol were also in vain. Under
basic conditions elimination-type products were
produced whereas the neutral protocol of
Mitsunobu hydroxy inversion 13 afforded the
starting alcohol; no SN2 displacement-type
products were observed. At this juncture we
decided to exploit the C6-C7 alkene 18 for further
functionalisation of B-ring. Treatment of
conjugated lactone 18 with m-CPBA (4 equi) in
CHCl3 at ambient temperature for 24-36 hr
furnished the expected C6-C7a-epoxide 19 (0
3.30, 3.38) as a single stereoisomer". The reaction
was stopped at 70-80% conversion because longer
exposure (48 hr) led to bis-epoxidation products.
Epoxide 19 marks another crucial synthon in this
series. Alcohol 15 and epoxide '19 are versatile
precursors for the synthesis of B-ring fluorinated,
aminated, and unsaturated 2-oxasteroids as
potential antiandrogenic and anabolic agents.
Conclusions
Our synthetic route to B-ring derivatives of 2-
oxasteroids is quite efficient, general in nature, and
should be serviceable for the synthesis of diverse
analogs. It exploits the C6-ketone as the precursor
for functional· group manipulation, which is
superior and versatile compared to the earlier ~ 6_
alkene. The Cl7-ethylenedioxy protecting group
survives most of the chemicals transformations,
except the DDQ oxidation. When desired, smooth
deketalisation can be effected with 10% aqueous
H2S04 in acetone. The screening of these steroidal
-






Scheme III- (i) PCC, CH2CI2, rt, 80%; (ii) MsCI, Et3N,
CH2CI2, -SaC, 30 min, 87%; (iii) LiBr, Li2C03, DMF, 100°C,
90%; (iv) m-CPBA, CHCI3, rt, 24-36 hr, 70-80%
lactones should reveal correlation of C6- and C7-
substitution with biological activity.
Experimental Section
General. IR spectra were recorded on a Jasco
5300 spectrometer. IH and DC NMR (PMR and
CMR) spectra were recorded on a Bruker ACF 200
instrument. Elemental analysis was performed on
a Perkin-Elmer 240C instrument. LRMS was
recorded on a Micromass VG70/70H instrument at
nCT, Hyderabad. Ozonolysis was carried out on
Welsbach model. SGC refers to silica gel
chromatography. Work-up means drying of
organic extracts with MgS04, solvent removal on a
rotary evaporator and concentration in vaccuo. All
reactions were carried out using standard syringe-
septum techniques in inert nitrogen atmosphere
with magnetic stirring. All reagents and solvents
were dried and distilled" before use.
17-(Ethylenedioxy)-3~ hydroxy-At-androst-
ene 7. Dehydroisoandrosterone (2.8 g, 10
mmoles), ethylene glycol (31.6 g, 28 mL, 500
mmoles) and p-TsOH (190 mg, 1 'mmolej lwere
taken in dry toluene (200 mL) and refluxed for 5 hr
with a Dean-Stark apparatus to remove water
formed during the reaction. The cooled reaction
mixture was immediately washed with saturated
NaHC03 solution and worked-up to afford 3.3 g of
pure ketal 7 in 98% yield; IR(KBr): 3472, 2918,
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1462 cm'; IH NMR (CDCI3): 8 0.86 (3H, s), 1.01
(3H, s), 3.44-3.60 (lH, m), 3.80-3.98 (4H, m), 5.34
(lH, d, J=6 Hz); l3C NMR (CDCI3): 8 14.l7,
19.39, 20.48, 22.76, 30.58, 31.23, 31.54, 32.17,
34.17, 36.53, 37.28, 42.22, 45.72, 49.98, 50.59,
64.49,65.11,71.49,119.50,121.30,140.81.
17-(Ethylenedioxy)-~ 4-3,6-androstenedione 8.
To a suspension ofPCC (3.2 g, 15 mmoles) in dry
DCM (20 mL) at room temperature was added the
ketal-alcohol 7 (1.0 g, 3 mmoles) and the reaction
mixture stirred for 24 hr at ambient temperature.
The reaction mixture was diluted with ether (50
mL) and filtered through a pad of Celite.
Evaporation of the solvent and filtration through
silica gel column gave 750 mg (70%) of the
diketone 8; IR(KBr): 3053,2947, 1684, 1456 cm';
IH NMR (CDCI3): 8 0.88 (3H, s), 1.15 (3H, s),
2.70 (lH, dd, J=12, 3 Hz), 3.80-3.98 (4H, m), 6.14
(1H, s); l3C NMR (CDCI3): 8 13.95, 17.30, 20.11,
22.65, 29.69, 33.69, 34.17, 35.28, 39.50, 45.56,'
45.75,50.19,50.52,64.33,65.02, 118.46, 125.22,
160.54, 198.89,201.44; Anal. Found: C, 73.20; H,
8.29. Calcd for C2IH2SO.:C, 73.23; H, 8.19%.
17-(Ethylenedioxy)-~ l,4-3,6-androstenedione
13a. The enedione 8 (600 mg, 1.7 mmoles) and
DDQ (1.5 g, 6.8 mmoles) were taken in dry
dioxane (40 mL) and refluxed for 72 hr in inert
nitrogen atmosphere. After cooling to room
temperature, the precipitated by-product was
filtered and the filtrate concentrated under reduced
pressure. The residue was dissolved in EtOAc (20
mL), washed with 2N NaOH (2x10 mL), and
worked-up. SGC afforded 200 mg (45%) of the
desired dienone 13a along with the deprotected
product 13b (200 mg, 45%).
Compound 13a: IR(KBr): 2943, 2881, 1699,
1657, 1620 cm'; IH NMR (CDCI3): 80.90 (3H, s),
1.19 (3H, s), 2.70 (1H, dd, J=12, 2 Hz), 3.78-3.94
(4H, m), 6.28 (IH, dd, J=9, 2 Hz), 6.34 (lH, d, J=2
Hz), 7.08 (lH, d, J=9 Hz); l3C NMR (CDCI3): 8
14.24, 18.98, 22.27, 22.42, 29.86, 33.83, 34.64,
44.78, 45.93, 46.18, 48.90, 50.06, 64.54, 65.25,
118.51, 124.88, 128.02, 153.51, 161.41, 185.00,
210,50; Anal. Found: C, 73.41; H, 7.58. Calcd for
C2IH260.: C, 73.66; H, 7.65%.
Compound 13b: IR(KBr): 2957, 1736~ 1660,
1620 em"; IH NMR (CDCl3): 60.98 (3H, s), 1.26
(3H, s), 2.84 (lH, dd, J=12, 2 Hz), 6.30 (IH, dd,
J=9, 2 Hz), 6.40 (1H, d, J=2 Hz), 7.08 (lH, d, J=9
Hz); l3C NMR (CDCI3): 8 13.77, 19.06, 21.66,
22.11, 30.90, 33.96, 35.45, 44.60, 45.51, 47.69,
48.96, 51.07, 125.27, 128.28, 153.11, 160.90,
185.l3, 200.91, 218.75.
17-(Ethylenedioxy)-I-hydroxy-2-oxa-~ 4_3, 6-
androstenedione 14. The dienone 13a (60 mg,
0.18 mmole) was dissolved in a 1:1 mixture of
DCMlpyridine (4 mL). Ozone was passed through
the solution at - 78° C for 20 min. After flushing
the excess 03, the reaction mixture was stirred for
15 min. at room temperature and then diluted with
15 mL CHCI3, washed with 1M HCI (3x10 mL)
and immediately with satd NaHC03 (2xl0 mL).
Work-up and SGC purification afforded 50 mg
(77%) of the ketolactol 14; IR(KBr) : 3375, 3059,
2945, 1732, 1460 cm'; IH NMR (CDCI3): 8 0.88
(3H, s), 1.22 (3H, s), 2.74 (1H, dd, J=12, 3 Hz),
3.98-3.80 (4H, m), 5.60 (IH, s), 6.45 (1H, s); l3C
NMR (CDCI3): 8 14.08, 18.42,20.09,22.48,29.68,
33. 14, 33.78, 42.86 (2C), 45.27, 45.63, 50.20,
64.53, 65.25, 100.69, 118.87(2C), 153.61, 163.31,
198.37.
17-(Ethylenedioxy) -2-oxa-6a-hydroxy-~ ·_3_
androstenone 15. The lactol 14 (50 mg, 0.13
mmole) was dissolved in CHCl3 (10 mL) and
NaBH. (52 mg, 1.3 mmoles) was added. To this
was added 2 mL of water followed by 0.2 mL of
1M NaOH. The reaction mixture was stirred for 4
hr at room temperature. Dilution with 10 mL
CHCI3, work-up and SGC purification furnished 37
mg (82%) of the hydroxy lactone 15; IR(KBr):
3489,3057,2939, 1709 cm'; IH NMR (CDCI3): 8
0.88 (3H, s), 1.22 (3H, s), 3.78-3.98 (4H, m), 4.03
(lH, d, J=12 Hz), 4.22 (1H, d, J=12 Hz), 4.25-4.36
(lH, m), 6.12 (lH, d, J=2 Hz); l3C NMR (CDCI3):
8 14.14, 17.28, 21.07, 22.66, 29.98, 33.87, 34.02,
38.39, 39.93, 45.57, 49.25(2C), 64.53, 65.23,
67.59, 77.l7, 110.89, 118.89, 164.94, 168.60;
Anal. Found: C, 69.23; H, 7.62. Ca1cd for
C2oH2S0S:C, 68.93; H, 8.10%.
17-(Ethylenedioxy)-2-oxa-~ 4_3, 6-androstene-
dione 16. 6-Hydroxylactone 15 (5 mg, 0.014
mmole) was added to a suspension ofPCC (20 mg,
0.084 mmole) in 1 mL dry DCM and the mixture
stirred for 2 hr at room temperature. Dilution with
5 mL ether, filtration through a pad of Celite,
work-up and SGC yielded 4 mg of the pure
compound 16; IR(CHC13): 3059, 2949, 1728, 1705
ern"; IH NMR (CDCI3): 8 0.89 (3H, s), 1.24 (3H,
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s), 2.75 (1H, dd, J=12, 2 Hz), 3.78-3.98 (4H, m),
4.15 (1H, d, J=10 Hz), 4.37 (1H, d, J=10 Hz), 6.37
(lH, s).
17-(Ethylenedioxy) -2-oxa-i14-6a-mesyloxy-
androsten-3-one 17. The hydroxy lactone 15
(15 mg, 0.043 mmole) was taken in 1
mL dry DCM. Et3N (65.3 mg, 90 J.LL,0.6 mmole),
followed by methanesulfonyl chloride (50 mg, 34
J.LL,0.43 mmole) were added at .:..5° C and the
mixture was stirred for 30 min. The solvent was
evaporated and the residue dissolved in 5 mL
EtOAc. The organic layer was washed with ice-
cold 1M HCI (10 mL), then with satd NaHC03. and
worked-up to provide 15 mg (87%) of mesylate
17; IR(CHCI3): 2947, 2891, 1761 cm'; IH NMR
(CDCI3): & 0.88 (3H, s), 1.26 (3H, s), 2.44-2.30
(1H, m), 3.12 (3H, s), 3.80-3.98 (4H, m), 4.04 (1H,
d,J=12 Hz), 4.27 (1H, d,J=12 Hz), 5.18-5.30 (1H,
m), 6.04 (1H, d, J=2 Hz).
17- (Ethylenedioxy) -2-oxa-i14,6-androsten-3-
one 18. To a solution of mesylate 17 (13 mg, 0.03
mmole) in dry DMF (1 mL), LiBr (26 mg, 0.3
mmole) and Li2C03 (22 mg, 0.3 mmole) were
added, and heated at 100° C for 1.5 hr. The cooled
reaction mixture was diluted with 10 mL water and
extracted with EtOAc (3x10 mL). Work-up and
SGC purification gave 4 mg (90%) pure compound
18; IR(CHCI3): 2928, 2878, 1722, 1624 cm'; IH
NMR (CDCI3): & 0.93 (3H, s), 1.18 (3H, s), 3.80-
4.00 (4H, rn), 4.05 (1H, d, J=12 Hz), 4.27 (lH, d,
J=12 Hz), 5.63 (IH, s), 6.16 (2H, s); MS: mlz 330
(M+), 268, 99, 86.
17-(Ethylenedioxy)-2-oxa-6, 7a-epoxy-i14-
androsten-3-one 19. To the diene 18 (5 mg, 0.015
mmole) in dry CHCl3 (1 mL), m-chloroperbenzoic
acid (10 mg, 0.06 mmole) was added and the
mixture stirred for 24 hr at room temperature. The
reaction mixture was diluted with 10 mL of CHCl3
and washed with satd sodium bicarbonate solution
and brine, dried and evaporated to give 19 ;
IR(CHCI3): 2926, 2826, 1734 cm'; IH NMR
(CDCI3): s 0.84 (3H, s), 1.09 (3H, s), 3.3U (IH, d,
J=4 Hz), 3.38 (lH, d, J=4 Hz), 3.74-3.90 (4H, m),
3.98 (IH, d, J=12 Hz), 4.02 (1H, d, J=12 Hz), 6.06
(IH, s).
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